Bictegravir/emtricitabine/tenofovir alafenamide for primary HIV infection: Efficacy, safety and impact on viral reservoir (the BIC-PHI clinical trial)


Por: Ambrosioni, J, de Lazzari, E, Sánchez-Palomino, S, Bailon, L, Suanzes, P, Busca, C, Ramos-Ruperto, L, Orviz, E, Rivero, A, Mothe, B, Del Romero, J, Falco, V, Vicens-Artés, S, Moraga, E, Cruceta, A, Mallolas, J and Miro, JM

Publicada: 1 nov 2025 Ahead of Print: 1 nov 2025
Resumen:
Objectives We evaluated the efficacy, safety and impact on viral reservoir of rapid bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) initiation during primary HIV infection (PHI). Methods Multicenter, single-arm clinical trial in participants with PHI of <3 months (seroconversion or incomplete serological pattern), starting BIC/FTC/TAF in 6 Spanish centers between January-2021 and September-2022. Primary endpoint was proportion of participants with viral load (VL)<50 copies/mL at 48-weeks on the Intention-to-treat-exposed population (ITTe). Cases were compared with randomly-matched retrospective PHI controls, starting other 3-drug Integrase-Strand-Transfer-inhibitor-based regimens. Reservoir was evaluated in PHI cases by Intact Proviral DNA Assay (IPDA). Results We included 64 participants, 94% cis-male, aged 32 (26;41) years.; 78% men-who-have-sex-with-men. At BIC/FTC/TAF initiation, Fiebig stages were II (14%), III (11%); IV (5%), V (54%) and VI (16%); VL was 496,520 (110,000;1,285,000) copies/mL; 62% were subtype B; median (IQR) CD4 T cell count was 406 (322;535) cells/mu L; 6% had active hepatitis B virus co-infection. All participants started BIC/FTC/TAF at first specialist consultation. 81% (ITTe) and 93% (On-Treatment, OT) had VL<50 copies/mL at 48-weeks. 72% had adverse events, only 3% were grade 3/4; 91% were not-related, none led to BIC/FTC/TAF-discontinuation. 92% of controls (OT) had VL<50 copies/mL at 48-weeks (p=0.914), 11% (17%) modified initial antiretroviral regimen (p>0.001). Intact and defective proviral DNA levels significantly decreased at 48-weeks. Conclusions BIC/FTC/TAF showed rapid viral decay, high suppression rates, good tolerability, and reservoir decline in PHI, making it an appealing regimen in this setting.

Filiaciones:
Ambrosioni, J:
 Univ Barcelona, Hosp Clin Barcelona HCB, Inst Invest Biomed August Pi i Sunyer FRCB IDIBAPS, Fundacio Recerca Clin Barcelona,HIV Unit, Barcelona, Spain

 Inst Salud Carlos III, CIBER Enfermedades Infecciosas CIBERInfec, Madrid, Spain

de Lazzari, E:
 Univ Barcelona, Hosp Clin Barcelona HCB, Inst Invest Biomed August Pi i Sunyer FRCB IDIBAPS, Fundacio Recerca Clin Barcelona,HIV Unit, Barcelona, Spain

 Inst Salud Carlos III, CIBER Enfermedades Infecciosas CIBERInfec, Madrid, Spain

Sánchez-Palomino, S:
 Univ Barcelona, Hosp Clin Barcelona HCB, Inst Invest Biomed August Pi i Sunyer FRCB IDIBAPS, Fundacio Recerca Clin Barcelona,HIV Unit, Barcelona, Spain

 Inst Salud Carlos III, CIBER Enfermedades Infecciosas CIBERInfec, Madrid, Spain

Bailon, L:
 Hosp Universitari Germans Trias & Pujol, Dept Infect Dis, Badalona, Spain

 Hosp Badalona Germans Trias & Pujol, Fundacio Lluita Infecc, Badalona, Spain

Suanzes, P:
 Univ Autonoma Barcelona, Hosp Univ Vall dHebron, Infect Dis Dept, Barcelona, Spain

Busca, C:
 Inst Salud Carlos III, CIBER Enfermedades Infecciosas CIBERInfec, Madrid, Spain

 Hosp Univ La Paz Carlos III, HIV Unit, IdiPAZ, Madrid, Spain

Ramos-Ruperto, L:
 Inst Salud Carlos III, CIBER Enfermedades Infecciosas CIBERInfec, Madrid, Spain

 Hosp Univ La Paz Carlos III, HIV Unit, IdiPAZ, Madrid, Spain

Orviz, E:
 Hosp Clin San Carlos, Ctr Sanitario Sandoval, IdISSC, Madrid, Spain

Rivero, A:
 Hosp Universitari Germans Trias & Pujol, Dept Infect Dis, Badalona, Spain

 Hosp Badalona Germans Trias & Pujol, Fundacio Lluita Infecc, Badalona, Spain

 BCN Checkpoint, Barcelona, Spain

:
 Inst Salud Carlos III, CIBER Enfermedades Infecciosas CIBERInfec, Madrid, Spain

 Hosp Universitari Germans Trias & Pujol, Dept Infect Dis, Badalona, Spain

 Hosp Badalona Germans Trias & Pujol, Fundacio Lluita Infecc, Badalona, Spain

 IrsiCaixa Fdn, Badalona, Spain

 Univ Vic Cent Univ Catalonia UVic UCC, Dept Infect Dis & Immun, Barcelona, Spain

Del Romero, J:
 Hosp Clin San Carlos, Ctr Sanitario Sandoval, IdISSC, Madrid, Spain

Falco, V:
 Univ Autonoma Barcelona, Hosp Univ Vall dHebron, Infect Dis Dept, Barcelona, Spain

Vicens-Artés, S:
 Univ Barcelona, Hosp Clin Barcelona HCB, Inst Invest Biomed August Pi i Sunyer FRCB IDIBAPS, Fundacio Recerca Clin Barcelona,HIV Unit, Barcelona, Spain

Moraga, E:
 Univ Barcelona, Hosp Clin Barcelona HCB, Inst Invest Biomed August Pi i Sunyer FRCB IDIBAPS, Fundacio Recerca Clin Barcelona,HIV Unit, Barcelona, Spain

Cruceta, A:
 Univ Barcelona, Hosp Clin Barcelona HCB, Inst Invest Biomed August Pi i Sunyer FRCB IDIBAPS, Fundacio Recerca Clin Barcelona,HIV Unit, Barcelona, Spain

Mallolas, J:
 Univ Barcelona, Hosp Clin Barcelona HCB, Inst Invest Biomed August Pi i Sunyer FRCB IDIBAPS, Fundacio Recerca Clin Barcelona,HIV Unit, Barcelona, Spain

 Inst Salud Carlos III, CIBER Enfermedades Infecciosas CIBERInfec, Madrid, Spain

Miro, JM:
 Univ Barcelona, Hosp Clin Barcelona HCB, Inst Invest Biomed August Pi i Sunyer FRCB IDIBAPS, Fundacio Recerca Clin Barcelona,HIV Unit, Barcelona, Spain

 Inst Salud Carlos III, CIBER Enfermedades Infecciosas CIBERInfec, Madrid, Spain

 Reial Acad Med Catalunya RAMC, Barcelona, Spain
ISSN: 01634453





Journal of Infection
Editorial
W. B. Saunders Co., Ltd., 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND, Reino Unido
Tipo de documento: Article
Volumen: 91 Número: 5
Páginas: 106651-106651
WOS Id: 001621418300001
ID de PubMed: 41207637
imagen gold

MÉTRICAS